◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Nuvalent Inc (NUVL)
Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-08-11
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Cifras clave
- Capitalización bursátil: $10 billion
- Ingresos (ejercicio cerrado en 2025-12-31): $0M
- Beneficio neto: ($425M)
Ver gráficos interactivos y estados completos →
Cuenta de resultados anual
| Cuenta de resultados | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|
| Ingresos totales | $0M | $0M | $0M | $0M | — |
| Ingresos operativos (EBIT) | ($414M) | ($280M) | ($150M) | ($86M) | — |
| Ingresos netos | ($425M) | ($261M) | ($126M) | ($82M) | — |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de NUVL. /companies/us/NUVL
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.